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AD dementia. The effectiveness of this test was evaluated for diagnostic accuracy. 
Diagnostic accuracy for identifying AD by ELISA was high (pooled sensitivity, 0.772 
(95% CI 0.747–0.796); pooled specificity, 0.732 (95% CI 0.699–0.762). ConClusions: 
Reduced CSF Ab1–42 levels are of potential utility in the differential diagnosis of AD 
versus non-AD dementias and healthy controls.
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objeCtives: Cystic fibrosis (CF) prevalence according to U. S. geographic region as 
well as patient age, gender and race was examined in the U. S. Medicaid population 
for patients younger than age 45. Methods: Patients ≤ 45 years from the Medicaid 
fee-for-service (FFS) population (2008-2009) were identified using International 
Classification of Disease 9th Revision Clinical Modification (ICD-9-CM) diagnosis 
code 277.0x. Patients were required to have continuous Medicaid FFS enrollment 
in both years and no evidence of managed care enrollment. CF prevalence was 
stratified by U. S. region, state, age group, gender and race, and was measured by 
number and percentage of patients in each category. Results: A total of 2,142 
patients were diagnosed with CF among the Medicaid FFS population under age 45 
years in 2008 and 2009. Prevalence was the highest (0.17%) for patients under age 17 
years, followed by those age 18-35 (0.14%), and 36-45 years (0.06%). However, some 
states had the highest CF prevalence in the 18-35 age range (Colorado: 0.92%; North 
Dakota: 0.50%; Kentucky: 0.54%). CF prevalence by race was also examined with 
the following results: White (0.17%), Hispanic (0.10%), Asian (0.07%), Black (0.06%) 
and Native American (0.03%). Male patients had a relatively higher prevalence 
than female patients (0.14% vs. 0.12%). The highest CF prevalence was observed in 
Colorado (0.47%), followed by Maryland (0.46%), North Dakota (0.31%), Ohio (0.28%) 
and Pennsylvania (0.27%). Patients residing in the Midwest U. S. region had the 
highest prevalence rate (0.15%), compared to the South (0.15%), Northeast (0.12%) 
and West (0.04%) regions. ConClusions: CF prevalence was the highest in patients 
age < 17 years nationwide, however, certain states showed the highest prevalence 
among patients age 18 to 35. White and male patients residing in the Midwest U. S. 
region were found to be at higher risk of a CF diagnosis.
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objeCtives: To examine claims-based relapse rates and time to relapse among mul-
tiple sclerosis (MS) patients treated with natalizumab or propensity score matched 
patients treated with platform therapy (interferon beta/glatiramer acetate) in the 
US. Methods: The Truven Health MarketScan Research Databases were used to 
identify adults with a MS (ICD-9-CM code 340) diagnosis treated with natalizumab 
or platform therapy; the first claim between January 1, 2009 and April 1, 2012 was the 
index. Patients had to have one year continuous enrollment pre- and post-index and 
remain on index therapy for 12 months. Patients were excluded if they used a non-
index therapy in the pre-index. Natalizumab and platform patients were propensity 
scored matched using nearest neighbor matching on demographic characteristics, 
selected comorbid conditions and medications, MS severity (using an adaptation 
of Kurtzke’s Functional System), pre-index relapse and pre-index expenditures. 
MS-relapse was defined as MS-related inpatient (IP) admission, IV or oral corticos-
teroid use. Cox Proportional Hazard models were used to evaluate time to relapse, 
controlling for demographic and pre-index clinical characteristics. Results: A total 
of 897 natalizumab patients met the study criteria, 882 of which were 1: 1 matched to 
882 platform therapy patients (mean age 45 years, 70% female) with a standardized 
difference < 10 on all matching measures. Compared to platform patients, natali-
zumab patients were significantly less likely to have MS-relapse post-index (26.5% 
vs. 35.5%, p< 0.001), with lower post-index rates of MS-related IP admissions (1.0% 
vs. 2.6%), IV-corticosteroid use (15.6% vs. 19.0%) and oral corticosteroid use (15.4% vs. 
23.1%) (all p< 0.001). Natalizumab patients also had 25 more relapse-free days (308 vs. 
283 days, p< 0.001). Post-index MS-relapse risk was lower for natalizumab patients 
(HR= 0.69, p< 0.001) after controlling for baseline characteristics. ConClusions: 
Natalizumab was associated with a significantly lower risk and rate of MS-relapse 
and had longer time to a MS-relapse compared to platform therapy.
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bACkgRound: The most common surgical complication associated with shunt 
placement in Hydrocephalus patients is obstruction causing shunt malfunction. 
The primary cause of obstruction is incorrect placement of the catheter tip, most 
notably in the choroid plexus. objeCtives: To investigate the clinical and eco-
nomic value of IGNS use in the accurate placement of catheters in Hydrocephalus 
patients. Methods: A search of the Embase and PubMed electronic databases was 
conducted to identify studies evaluating the accuracy, effectiveness, quality-of-life 
(QOL) and economic aspects of IGNS in patients with Hydrocephalus. No language 
restrictions were applied. Results: We conducted a meta-analysis of studies report-
ing accuracy of ventricular catheter placement in patients with hydrocephalus 
undergoing shunt placement with stereotactic IGNS versus freehand technique. The 
definition of accurate catheter placement was similar in all studies. The meta-analysis 
showed the odds of achieving an accurate catheter placement for surgeons who utilize 
IGNS was almost 6 times higher (odds ratio 5.55, 95% CI [2.84, 10.85], P< 0.00001) than 
surgeons who used freehand placement techniques. Furthermore, accurate place-
burden. Improving the control of PD motor symptoms on patients may contribute 
to prevent anxiety and HRQoL deterioration in caregivers.
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objeCtives: Gaucher disease (GD) is an inherited, rare, lysosomal storage disorder 
caused by a genetic deficiency of glucocerebrosidase. The result is the accumulation 
of the substrate, glucosylceramide, in the lysosomes of macrophage cells in the liver, 
spleen, bones, lungs, and other vital tissues. Three subtypes of Gaucher disease are 
recognized: type 1 (GD1, non-neuropathic), type 2 (GD2, acute neuropathic), and type 
3 (GD3, subacute/chronic neuropathic). Clinical manifestations of the disease are mul-
tisystemic, clinically heterogeneous and require lifelong management. Methods: 
To better understand the burden of GD, a comprehensive review of the published 
literature was conducted. MEDLINE, EMBASE, CENTRAL and “grey” literature sources 
published in English between January 1990 and February 2013 were searched for rel-
evant publications. Results: A total of 97 publications focusing on the epidemiologic, 
clinical, and socioeconomic burden of GD, treatment options and guidelines were 
summarized. The standardized incidence and prevalence of GD in the general popu-
lation varies from 0.30 to 5.80 per 100,000 and 0.33 to 1.75 per 100,000, respectively, 
and GD1 is the predominant type in most regions. The risk of mortality is highest in 
GD patients younger than age 5 years and generally increased after age 55; the life 
expectancy is lower than the general population. Common manifestations of GD such 
as anemia, thrombocytopenia, splenomegaly, hepatomegaly and bone disease lead 
to a decreased quality of life. Reported GD comorbidities include Parkinson’s disease 
and cancer. Current treatment options consist of enzyme replacement therapy (ERT, 
standard of care) and substrate reduction therapy (SRT). ERT is the standard of care, 
though unmet needs still exist, especially for GD2 and GD3. ConClusions: GD is a 
rare, chronic disease associated with significant burden to patients and caregivers. 
While ERT is an effective and well-established treatment for GD patients, several 
unmet needs exist and further research is needed in this area.
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objeCtives: Restless leg syndrome (RLS) is a condition with possibly high prevalence 
in hemodialysis (6-60% according to the literature), and a specific treatment available. 
Thus it’s important to identify it among other conditions present in this population 
that might confound diagnosis (such as peripheral vascular disease or neuropathies). 
An approach based on a self-completed screening test will be assessed in this study, 
along with an estimation of RLS prevalence in hemodialysis. Methods: Patients 
from two hemodialysis units answered a RLS screening test. Those with a positive 
screening completed the International Restless Legs Syndrome Study Group Rating 
Scale (IRLS) that assesses symptom severity. A neurophysiologist performed a clini-
cal interview to confirm the diagnosis, including a supervised administration of the 
IRLS. Results: 164 patients were recruited. Mean age was 65.7 years (range 33-87; 
Pct25-75: 55.5-77.5), 67% were male and mean time in dialysis was 64.16 months. 
Self-completed screening test identified 69 possible cases of RLS (42.07%). 44 (26.8%) 
patients had RLS symptoms according to the self-completed IRLS, and 79% of them 
were classified as having moderate to severe RLS symptoms. The clinician confirmed 
just 22 of those cases (13.4% of the total sample), with a demographic profile similar 
to the sample. The screening test had in this sample a sensitivity of 100%, specificity 
66.43% and positive predictive value 31.88%. ConClusions: This study found RLS is 
a relatively common condition in hemodialysis patients. The screening test showed 
a high sensitivity to detect RLS, but very low specificity, so the confirmation of an 
expert neurologist or neurophysiologist is neccesary.
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objeCtives: The purpose of this study was to carry out systematic review of the 
literature and meta-analysis to evaluate the diagnostic utility of cerebrospinal fluid 
(CSF) levels of the 42 amino acid form of amyloid-b (Ab1−42) as a biomarker for dif-
ferentiating Alzheimer’s disease (AD) from non-AD dementia. Methods: Design - 
Systematic literature review was used to evaluate the effectiveness of the Ab for the 
diagnosis of Alzheimer’s disease. The Scottish Intercollegiate Guidelines Network 
(SIGN) tool was used by two evaluators to evaluate independently the quality of the 
15 studies. Data sources - The literature review covered from October 27, 1946, to 
October 22, 2013, and searched eight domestic databases including Korea Med and 
international databases including Ovid-MEDLINE, EMBASE, and Cochrane Library. 
Eligibility criteria for selecting studies - Primary criteria for inclusion were valid 
studies on (i) patients with mild cognitive impairment with confirmed or suspected 
AD and non-AD dementia, and (ii) assessment of Ab1−42levels using appropriate 
comparative tests. Results: A total of 15 studies (15 diagnostic evaluation stud-
ies) were identified in which levels of CSF Ab1−42 were assessed. Meta-analysis 
was performed on nine robust studies that compared confirmed AD with healthy 
individuals (n = 1587), 10 studies that compared AD with non-AD dementias (n = 
860), and four studies that compared a-MCI (amnestic mild cognitive impairment) 
with na-MCI (non-amnestic mild cognitive impairment) subjects (n = 857). Overall, 
Ab1–42levels were reduced in CSF from AD patients versus healthy controls or non-
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objeCtives: Time to 12-week confirmed disability progression, measured by the 
Expanded Disability Status Scale (EDSS), is a key endpoint in RRMS trials. However, 
the EDSS has widely discussed limitations, and several therapies have shown 
inconsistent results for this endpoint in terms of statistical significance. Here 
we contextualize differences in 12-week confirmed disability progression results 
in the Phase 3 studies of gastro-resistant dimethyl fumarate (DMF), DEFINE and 
CONFIRM. Methods: Time to 12-week confirmed disability progression at 2 years 
was a secondary endpoint in both studies; however, the studies were not powered 
to detect statistical significance for this endpoint. Patients had the option of dis-
continuing study treatment and initiating alternative therapy at any time due to 
12-week confirmed disability progression or after completing 48 weeks of study 
treatment and experiencing one confirmed relapse after 24 weeks (DEFINE) or two 
confirmed relapses at any time (CONFIRM). Results: Although gastro-resistant 
DMF 240mg BID demonstrated consistent reductions on 12-week confirmed dis-
ability progression, statistical significance was achieved in DEFINE (p= 0.0050) but 
not CONFIRM (p= 0.2536). There was an apparent difference in the placebo rate 
of 12-week confirmed disability progression at 2 years (DEFINE, 27%; CONFIRM, 
17%). In CONFIRM, a relatively higher percentage of placebo patients (4.1%) versus 
gastro-resistant DMF patients (1.7%) switched to alternative MS therapy or with-
drew after the time of tentative disability progression without a subsequent EDSS 
assessment. Additionally, a relatively higher percentage of placebo patients who 
switched to alternative MS therapy had ≥ 2 relapses without 12-week confirmed 
disability progression prior to switch in CONFIRM (45%) compared with DEFINE 
(16%). ConClusions: Relapse-based criteria for switching to alternative therapy 
may have contributed to the lower placebo progression rate and decreased assay 
sensitivity for this particular endpoint in CONFIRM. The totality of evidence needs 
to be taken into account when assessing a therapy’s effect on disability progression.
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objeCtives: To examine annual prevalence and treatment rates of multiple 
sclerosis (MS) patients using a large US commercial administrative claims data-
base. Methods: Random sample of 5 million lives from the IMS LifeLink Plus 
database was used for this analysis. Individuals with ≥ 1 month eligibility were 
included in the denominator; those with ≥ 1 month eligibility and an MS diagnosis 
(ICD-9-CM: 340. xx) were included in the numerator. Presence of a disease-modifying 
drug (DMD) was defined as ≥ 1 claim during the calendar year of interest. Baseline 
demographics and clinical characteristics were evaluated for each group. Annual 
prevalence (per 10,000) and treatment rates were reported for each calendar year 
(2006–2012) and were further stratified by age and gender. Results: MS patients 
were older than patients without MS (mean age range 46.8–47.7 vs. 34.4-35.1, respec-
tively) and more likely to be female (73% vs. 51%, respectively). Comorbidities such as 
gastrointestinal disorders (42.8%), hypertension (43.5%), arthritis (24.8%) and anxiety 
(22.8%) were common among MS patients (2006 estimates). MS prevalence ranged 
from 16.4/10,000 (2006) to 17.8/10,000 (2010). Similar patterns over the years were 
observed when data were stratified by sex and age, with absolute rates being higher 
among women vs. men (24.4/10,000 vs. 8.2/10,000, respectively; 2012; P< 0.001) and 
patients aged 45–64 years (29.4/10,000 vs. 0.4/, 15.6/ and 18.2/10,000 patients aged 
< 18, 18–44 and ≥ 65, respectively; P< 0.001). The proportion of MS patients receiv-
ing a DMD increased from 2006 (42.5%) to 2012 (51.2%) (P< 0.001). Similar rates and 
trends in the proportion of patients with a DMD were observed when stratified 
by gender (42.8% (2006) and 51.3% (2012) [female]; 41.5% (2006) and 50.7% (2012) 
[male]; both P< 0.001). ConClusions: In a recent 5-year period, MS prevalence 
in a large US insured population increased slightly, with a greater increase in the 
likelihood of DMD use.
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objeCtives: Multiple Sclerosis (MS) is a chronic disease of the Central Nerve 
System. The aim of this paper is to characterize the various clinical and demographi-
cal feature of the MS population. Methods: In a 6-month cross-sectional study248 
patients were investigated in Khorasan provinces. Data was collected by employing 
a 32- item self-administered questionnaire in a face to face interview. Results: 
A total of 248 patients were recruited (186 female, 75%; 62 male, 25%). The mean 
age was 31.9±8.7, the mean onset age was 26.3 (26.3±8: 1) and the median dura-
tion of illness was 3.8 years. The prevalence and incidence were estimated to be 
25/100000 and 2.5/100,000 respectively. Significantly more patients had a Relapsing 
Remitting MS course. Self reported character of MS individuals were significantly 
more (193, 77.8%) regarding nervous character (p value= .000). A family history of 
ms was reported in 11%. However, there was no a significant difference between 
men and women with respect to age, age of onset, BMI, disease duration and gap 
between clinical onset and diagnosis. The education level was reported as 154 (62%) 
had a bachelor and greater degree and 94 (38%) had a diploma or under-diploma 
degree. Thirty six percents of the patients were born in the spring. ConClusions: 
In contrast to reports from Caucasians, the Iranian differs with respect to age, age 
of onset of illness, disease duration, family history, sex ratio. The sex ratio of 3: 1 
in this study is somewhat higher than the usual 2: 1 in the standard text and seen 
in Asia or the neighboring Arab countries. This might reflect the role of hormone 
or genetic factors or much more visiting by women, or women stressful life. These 
included BMI, birth season, education stand. The educated people in developing 
country are probably likely to adopt a “western” lifestyle, therefore more probably 
to get the risk of developing Western disease.
ment of the catheter tip was associated with fewer shunt failures, as demonstrated in 
9 clinical studies investigating accurate catheter placement using the AxiEM™ IGNS 
(Medtronic Inc). In addition to being costly, studies showed shunt revision surgery 
was associated with significant morbidity and lower long-term QOL. In a study of 80 
paediatric Hydrocephalus patients, investigators found that patients with a history 
of two or more shunt revision surgeries had a significantly worse QOL (p< 0.02), as 
measured by the Hydrocephalus Outcomes Questionnaire (HOQ). ConClusions: The 
use of IGNS significantly increases the accuracy of ventricular catheter placement 
compared to freehand techniques in hydrocephalus patients undergoing ventricular 
shunt insertion. Clinical studies have shown the use of IGNS in shunt placement 
surgery results in lower shunt failure rates, which improve QOL and lowers the eco-
nomic impact to payers.
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objeCtives: Teriflunomide and dimethyl fumarate (DMF), oral therapies for relaps-
ing–remitting multiple sclerosis (RRMS), have demonstrated efficacy in clinical trials. 
Despite challenges in comparing outcomes across studies, exploratory analyses 
of treatment effects can be compared informally using relative reductions in a 
specific endpoint. However, these outcomes do not account for differences in dis-
ease severity among study populations or differences on very low event rates. The 
number needed to treat (NNT) to prevent an event is an important outcome to 
consider for any comparisons within the field of MS. Methods: NNTs were derived 
using data from studies with teriflunomide 14 mg (TEMSO, NCT00134563; TOWER, 
NCT00751881) or DMF (DEFINE, NCT00420212; CONFIRM, NCT00451451) based on 
inverse of absolute differences between treatment and placebo groups. Results: 
Teriflunomide studies included patients with progressive disease; patients in 
DEFINE had slightly lower Expanded Disability Status Scale scores. Teriflunomide 
and DMF significantly reduced risk of relapse (all studies). NNTs to prevent one 
relapse were similar across studies (5.9 [TEMSO], 5.6 [TOWER], 5.3 [DEFINE], 5.6 
[CONFIRM]). Risk of disability progression sustained for 12 weeks was significantly 
reduced in TEMSO, TOWER, and DEFINE but not CONFIRM. Corresponding NNTs to 
prevent disability progression were 13.8, 17.4, 10.8, and 30.2. Risk of relapse leading 
to hospitalization was significantly reduced in TEMSO and TOWER but not in DEFINE 
and CONFIRM. Corresponding NNTs were lower in TEMSO (12.5) and TOWER (20) 
than in DEFINE (50) and CONFIRM (50). ConClusions: Using the NNT approach, we 
demonstrate a comparable effect size for teriflunomide and DMF on relapse. NNTs 
to prevent disability progression with teriflunomide showed a consistent signifi-
cant reduction in risk versus placebo in both TEMSO and TOWER, whereas for DMF, 
comparable NNTs were observed only in DEFINE, and not in CONFIRM. Reduction 
of risk for relapse leading to hospitalization was significant only for teriflunomide.
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objeCtives: Alzheimer’s Disease (AD) destroys brain cells, causing problems 
with memory, thinking, and behavior severe enough to affect work, family and 
social relationships, and basic activities of daily living. AD gets worse over time, 
it is incurable and fatal. Donepezil, galantamine, rivastigmine and memantine 
are the current treatment options but the latest evidence was not systematically 
reviewed recently. Methods: PubMed, Health Technology Assessment Database, 
NHS Economic Evaluation Database, Cochrane Central Register of Controlled 
Trials, Cochrane Database of Systematic Reviews, DAHTA-Datenbank, PSYNDEX 
and PsycINFOwere searched systematically for randomized-controlled studies. 
For the abstracts that met the pre-defined inclusion criteria, full text articles were 
obtained. The abstracts that did not meet the search criteria were excluded. Based 
on these manuscripts it was evaluated whether each study meets the selection cri-
teria. Results: After elimination of duplicates the search indicated above yielded 
418 articles of which another 299 were excluded based on the title selection; after 
abstract review, 82 articles have been reviewed in full text which were also deemed 
to be relevant based on the research question. For donepezil 24 RCTs were available 
for which another 4 subgroup and exploratory analyses have been published. For 
galantamine 11 RCTs with 6 exploratory analysis are available. For rivastigmine 10 
RCTs are available with 7 exploratory papers. For memantine 14 RCTs with 6 explora-
tory analysis were found. Out of those studies eleven head-to-head studies are avail-
able; 5 studies comparing donepezil vs memantine, 3 studies comparing donepezil vs 
rivastigmine and one study each comparing donepezil vs galatamine, rivastagmine 
vs memantine. There was one study comparing rivastagmine vs donepezil vs galan-
tamine. In comparison the clinical evidence seems diverse dependent on the patient 
characteristics, study duration, and severity of disease. ConClusions: Appropriate 
evidence assessment for the approved AD treatments requires clinical expertise and 
close review of the study characteristics.
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